| MeSH term | MeSH ID | Detail |
|---|---|---|
| Angioedema | D000799 | 6 associated lipids |
| Anus Diseases | D001004 | 3 associated lipids |
| Apraxias | D001072 | 1 associated lipids |
| Arm Injuries | D001134 | 1 associated lipids |
| Arterial Occlusive Diseases | D001157 | 12 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
| Arthritis, Experimental | D001169 | 24 associated lipids |
| Arthritis, Infectious | D001170 | 8 associated lipids |
| Arthritis, Juvenile | D001171 | 8 associated lipids |
| Ascites | D001201 | 25 associated lipids |
| Ataxia | D001259 | 20 associated lipids |
| Ataxia Telangiectasia | D001260 | 6 associated lipids |
| Autoimmune Diseases | D001327 | 27 associated lipids |
| Autonomic Nervous System Diseases | D001342 | 4 associated lipids |
| Bacterial Infections | D001424 | 21 associated lipids |
| Balanitis | D001446 | 4 associated lipids |
| Beckwith-Wiedemann Syndrome | D001506 | 1 associated lipids |
| Behcet Syndrome | D001528 | 7 associated lipids |
| Biliary Fistula | D001658 | 13 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Shihab FS et al. | Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. | 2008 | Transplantation | pmid:18475181 |
| Rosen HR et al. | Significance of early aminotransferase elevation after liver transplantation. | 1998 | Transplantation | pmid:9448146 |
| Prókai à et al. | Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts. | 2016 | Transplantation | pmid:26502369 |
| Calmus Y et al. | Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. | 2010 | Transplantation | pmid:20495510 |
| Egli A et al. | Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. | 2009 | Transplantation | pmid:19935369 |
| Selzner N et al. | Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. | 2009 | Transplantation | pmid:19935376 |
| Heeckt PF et al. | Functional impairment of enteric smooth muscle and nerves caused by chronic intestinal allograft rejection regresses after FK506 rescue. | 1995 | Transplantation | pmid:7530870 |
| Lee D et al. | Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. | 2017 | Transplantation | pmid:27779572 |
| Gayowski T et al. | Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. | 1998 | Transplantation | pmid:9500623 |
| Neylan JF | Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. | 1998 | Transplantation | pmid:9500626 |
| Budde K et al. | Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. | 2007 | Transplantation | pmid:17318074 |
| Takeguchi N et al. | Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine. | 1993 | Transplantation | pmid:7681229 |
| Valdivia LA et al. | Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. | 1993 | Transplantation | pmid:7681230 |
| Shapiro R et al. | A prospective randomized trial of FK506-based immunosuppression after renal transplantation. | 1995 | Transplantation | pmid:7533343 |
| Bundick RV et al. | FK506 as an agonist to induce inhibition of interleukin 2 production. | 1992 | Transplantation | pmid:1374947 |
| Cox KL et al. | An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. | 1995 | Transplantation | pmid:7533344 |
| Sakr M et al. | The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats. | 1992 | Transplantation | pmid:1374948 |
| Gupta A et al. | Elevated myeloid: plasmacytoid dendritic cell ratio associates with late, but not early, liver rejection in children induced with rabbit anti-human thymocyte globulin. | 2009 | Transplantation | pmid:19696644 |
| Jain A et al. | Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. | 2008 | Transplantation | pmid:18347534 |
| Khanna A et al. | Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. | 1999 | Transplantation | pmid:10071036 |
| Kessler M et al. | A renal allograft recipient with late recurrence of focal and segmental glomerulosclerosis after switching from cyclosporine to tacrolimus. | 1999 | Transplantation | pmid:10071045 |
| Singh N et al. | Pulmonary infections in liver transplant recipients receiving tacrolimus. Changing pattern of microbial etiologies. | 1996 | Transplantation | pmid:8610349 |
| Johansson A and Möller E | Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. | 1990 | Transplantation | pmid:1701570 |
| Reyes J et al. | Expressive dysphasia possibly related to FK506 in two liver transplant recipients. | 1990 | Transplantation | pmid:1701571 |
| Horner BM et al. | Recipient damage after musculocutaneous transplant rejection. | 2008 | Transplantation | pmid:18946349 |
| Textor SC et al. | Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. | 1993 | Transplantation | pmid:7685934 |
| di Francesco F et al. | One year follow-up of steroid-free immunosuppression plus everolimus in isolated pancreas transplantation. | 2008 | Transplantation | pmid:18946356 |
| Higgins RM et al. | Acute rejection after renal transplantation is reduced by approximately 50% by prior therapeutic blood transfusions, even in tacrolimus-treated patients. | 2004 | Transplantation | pmid:14966430 |
| Mahé E et al. | Drug-induced hypersensitivity syndrome associated with primary Epstein-Barr virus and human herpesvirus 6 infections in a child intestinal transplant recipient. | 2004 | Transplantation | pmid:14966435 |
| Boillot O et al. | Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation: a pilot study. | 1998 | Transplantation | pmid:9825815 |
| Woodle ES et al. | FK506: inhibition of humoral mechanisms of hepatic allograft rejection. | 1992 | Transplantation | pmid:1379749 |
| Uchida N et al. | Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone. | 2011 | Transplantation | pmid:21677598 |
| Mourad M et al. | Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. | 2005 | Transplantation | pmid:16249748 |
| Hariharan S | Case 2: strategies to minimize the use of calcineurin inhibitors (CNIs). | 2002 | Transplantation | pmid:12357988 |
| Stempfle HU et al. | The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. | 2002 | Transplantation | pmid:11889427 |
| Vafadari R et al. | Inhibitory effect of tacrolimus on p38 mitogen-activated protein kinase signaling in kidney transplant recipients measured by whole-blood phosphospecific flow cytometry. | 2012 | Transplantation | pmid:22643331 |
| Schena FP et al. | Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. | 2009 | Transplantation | pmid:19155978 |
| Morales JM et al. | Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. | 2008 | Transplantation | pmid:18724234 |
| Muraki T et al. | Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. | 1995 | Transplantation | pmid:7544038 |
| Aw MM et al. | Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience. | 2003 | Transplantation | pmid:12660504 |
| Hebert MF et al. | Interpreting tacrolimus concentrations during pregnancy and postpartum. | 2013 | Transplantation | pmid:23274970 |
| Thai NL et al. | Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. | 2006 | Transplantation | pmid:17198253 |
| Ueki S et al. | Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. | 2006 | Transplantation | pmid:17198266 |
| Lorber MI et al. | A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. | 1991 | Transplantation | pmid:1713364 |
| Abu-Elmagd K et al. | The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. | 1991 | Transplantation | pmid:1713365 |
| Jain A et al. | One thousand consecutive primary liver transplants under tacrolimus immunosuppression: a 17- to 20-year longitudinal follow-up. | 2011 | Transplantation | pmid:21378604 |
| Gruessner RW et al. | Portal donor-specific blood transfusion and mycophenolate mofetil allow steroid avoidance and tacrolimus dose reduction with sustained levels of chimerism in a pig model of intestinal transplantation. | 2004 | Transplantation | pmid:15239611 |
| Macphee IA et al. | Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. | 2005 | Transplantation | pmid:15729180 |
| Bendahan J et al. | The effect of administration of FK506 on delayed regeneration in flushed partially hepatectomized livers. | 1994 | Transplantation | pmid:7511255 |
| Krämer BK et al. | Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial. | 2012 | Transplantation | pmid:22858806 |